** Shares of vaccine developer Vaxcyte Inc PCVX.O fall 3% to $36.69
** Brokerage Leerink cuts PCVX's PT to $65 from $153
** PCVX said on Monday its experimental pneumococcal vaccine for infants, VAX-24, achieved "non-inferiority" in a mid-stage study compared to rival Pfizer's PFE.N Prevnar 20 shot
** Although we believe that VAX-24 is a safe and approvable vaccine, we now have less confidence that both VAX-24 & VAX-31 will deliver highly compelling efficacy in future infant datasets - brokerage
** Leerink notes that the infant results do not affect its high expectations for VAX-31 in adults
** PCVX shares have faced significant pressure due to investor concerns about U.S. health secretary Robert F. Kennedy Jr.'s stance on vaccines, Leerink says
** Up to last close, PCVX was down ~54% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。